A Phase II, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Two Different Doses of Abatacept (BMS-188667) Administered Intravenously to Japanese Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate.

Trial Profile

A Phase II, Multi-Center, Randomized, Double-Blind, Placebo Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Two Different Doses of Abatacept (BMS-188667) Administered Intravenously to Japanese Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2011

At a glance

  • Drugs Abatacept; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Nov 2008 Actual patient number (194) added as reported by ClinicalTrials.gov.
    • 20 Mar 2008 Status changed from in progress to completed, in accordance with clinicaltrials.gov.
    • 18 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top